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Abstract The human foamy virus proteinase was expressed in
fusion with maltose binding protein in Escherichia coli and
purified. The specific activity of the fusion protein was similar to
that of the processed enzyme. The kinetic constants on foamy
virus cleavage site substrates were very low but comparable to
those obtained with the gag-encoded avian proteinase on its own
substrates. The proteinase showed preference for high ionic
strength and a pH optimum of 6.6. None of the tested retroviral
cleavage site peptides were substrates, however, some peptides
representing cleavage sites in retrotransposons were properly
processed by the enzyme.
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1. Introduction
The retroviral proteinase (PR) plays a crucial role in the
maturation of virus by processing the Gag and Gag-Pol poly-
proteins [1]. The PR of HIV is a very good target for chemo-
therapy of AIDS and several PR inhibitors are now in clinical
use [2]. Much less is known about the structure and speci¢city
of the proteinase of another human retrovirus, that of the
human foamy virus (HFV). Retroviruses of the foamy virus
subgroup have several unusual features: the Pol protein is
synthesized independently from Gag, viral particles contain
almost full length reverse-transcribed linear cDNA, and the
nucleocapsid domain does not have the consensus zinc ¢nger
motif [3,4]. In addition, Gag does not appear to be e⁄ciently
processed, except at one site close to the C-terminus [4]. Mu-
tation of the putative HFV PR active site resulted in non-
infectious virions, suggesting that the PR is essential for viral
infectivity [5]. In a vaccinia virus expression system HFV PR
was able to cleave HFV Gag, however, it did not cleave other
retroviral Gag precursors [6]. A 100 residue long HFV PR was
cloned and found to be active as part of a thioredoxin fusion
protein, but the activity was lost after elimination of the het-
erologous protein part fused with the enzyme coding sequence
[7]. Later the HFV PR was cloned with C-terminal His-tag
and this enzyme was used to determine the cleavage sites in
the Pol polyprotein [8]. However, no kinetic data have thus
far been reported on the enzyme. Here we report the expres-
sion of a 141 residue long part of the HFV as a fusion protein
with maltose binding protein. The e¡ect of salt on the enzyme
activity as well as the pH pro¢le of the enzyme have been
determined, and the speci¢city of the proteinase was charac-
terized using oligopeptides representing cleavage sites of var-
ious retroviruses and retrotransposons.
2. Materials and methods
2.1. Cloning of the HFV PR
A 451 bp DNA containing the putative HFV PR coding region of
the plasmid p13HFV (kindly provided by Dr. R. Flu«gel, Germany),
derived by PCR ampli¢cation was cloned into the XmnI and BamHI
sites of pMAL-c2 vector (New England Biolabs) after the maltose
binding protein (MBP) gene, to produce pMBP-HFVPR. DNA se-
quencing reaction of the cloned proteinase was performed with ABI-
Prism dye terminator cycle sequencing kit (Perkin-Elmer) and ana-
lyzed on an Applied Biosystem Model 373A Sequencer. The protein
sequence coded by pMBP-HFVPR, as compared to the sequence of
HIV-1 and HTLV-1 PRs, is shown in Fig. 1. For the puri¢cation of
the fusion protein 500 ml freshly prepared Escherichia coli cultures
bearing the plasmid construct were grown at 37‡C up to an absorb-
ance at 600 nm of 0.2^0.5, in Luria-Bertani medium containing 0.1%
(w/v) ampicillin. Then, induction with IPTG (1.0 mM) was done for
2 h and cells were harvested by centrifugation at 2000Ug for 20 min
at 4‡C. After removal of the supernatant, 25 ml of lysis bu¡er (20 mM
Tris, pH 7.4, 1 mM EDTA, 200 mM NaCl, 1 mM DTT) was added.
Cells were disrupted by freezing-thawing followed by sonication on
ice. Then, samples were centrifuged at 9000Ug for 30 min at 4‡C, the
supernatant was diluted ¢vefold with lysis bu¡er, loaded on a column
containing amylose resin (3 ml), and extensively washed with the lysis
bu¡er. The fusion protein was eluted with lysis bu¡er containing 10
mM maltose. Fractions containing high absorbance at 280 nm were
pooled. Typically 12^17 mg fusion protein was obtained per gram wet
weight of E. coli cells. Cleavage of the isolated fusion protein was
performed with factor Xa by 2 h incubation at 37‡C. The mixture
of the cleaved protease and MBP was puri¢ed by gel ¢ltration chro-
matography, in a Superdex G-75 HR 10/30 column (Pharmacia),
equilibrated in 50 mM Tris, pH 8.3, containing 4 M guanidine-HCl.
Collected fractions containing the protease were dialyzed against bu¡-
er without guanidine-HCl, to regain activity. Purity of the proteinase
was assessed by SDS-PAGE, using 10^20% gradient gels. The amino-
terminal sequence of the processed protease was determined after
SDS-PAGE and electrotransfer to a polyvinylidene di£uoride-type
membrane using a Knauer Model 910 protein sequencer. Protein con-
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centrations were determined by the Bradford spectrophotometric
method [9]. Rabbit antiserum against the conserved active site region
of the HFV protease [10] was used for immunoblotting.
2.2. Proteolytic assay
Oligopeptides were synthesized as described previously [11]. The PR
assays were initiated by the mixing of 5 Wl puri¢ed fusion proteinase
or processed proteinase (15^130 WM) with 10 Wl 2Uincubation bu¡er
(0.1 M MES, 0.2 M Tris, 0.1 M acetate and 2 M NaCl, pH 6.6) and
5 Wl 0.01^0.6 mM substrate at 37‡C for 1 or 2 h. The reaction was
stopped by the addition of 180 Wl 1% tri£uoroacetic acid, and an
aliquot was analyzed by reversed-phase HPLC as described previously
[11]. Oligopeptides not hydrolyzed during the 2 h period were assayed
at 0.2 mM ¢nal substrate concentration by incubating them with 50
WM enzyme overnight. Based on the detection limit of the assay, the
estimated kcat threshold value for these substrates is smaller than
1U1035 s31. Cleavage products of PR-catalyzed hydrolysis were iden-
ti¢ed by amino acid analysis and/or by N-terminal sequencing. Ki-
netic parameters were determined by ¢tting the data obtained at less
than 20% substrate hydrolysis to the Michaelis^Menten equation (or
to linear equation if KmH[S]) by using the Fig. P program (Fig. P
Software Corp.).
2.3. Determination of the ionic strength e¡ect on the activity,
pH optimum and urea denaturation curve of the enzyme
The pH optimum of the enzyme was determined in 100 mM MES,
200 mM Tris, 100 mM acetate bu¡er, in the pH range of 5^8, in the
presence of 0.15 mM substrate. The e¡ect of ionic strength was de-
termined at pH 7.0 in the same bu¡er by the addition of NaCl to the
indicated ¢nal concentration. Urea dissociation curve was determined
in the presence of 1 M NaCl in the same bu¡er by addition of urea to
the indicated ¢nal concentration
3. Results
Using a template plasmid containing an infectious HFV
clone [12], the 5P region of HFV containing the PR coding
sequence (Fig. 1) was ampli¢ed by PCR, the obtained DNA
was cloned into pMAL-c2, and expressed in fusion with MBP
in E. coli. The fusion protein was puri¢ed on amylose resin,
followed by gel ¢ltration under denaturing conditions, as
shown in Fig. 2. The puri¢ed chimeric protein cleaved an
oligopeptide substrate (SRAVN*TVTQS, asterisk indicates
the site of cleavage) having the cleavage site sequence in the
nucleocapsid domain of the Gag [7] at the expected site as
determined by Edman degradation and amino acid analysis of
the fragments (Fig. 3). Oligopeptides representing the Pol
cleavage sites of HFV were also hydrolyzed at the sites pre-
viously determined [8], and kinetic parameters were deter-
mined for some of these peptides (Table 1). While the Km
value was within the expected range, the obtained catalytic
constants were much lower than those we previously deter-
mined for various mammalian retroviral proteinases coded on
pol genes [13^15] but similar to those obtained with gag-en-
coded avian PR [11]. The avian PR is produced in an equi-
molar amount to the structural Gag proteins, while pol-
encoded PRs are present in only 10^20-fold lower concen-
tration in the virion. It is important to note that the HFV
PR contains a Ser in the active site triplet, similar to the avian
PR as well as yeast retrotransposons, as compared to Thr in
the PR of HIV and most other retroviruses (see Fig. 1). Fur-
thermore, substitution of Ser to Thr in the avian enzyme
substantially increased its activity [16] while the reverse muta-
tion in HIV-1 PR decreased the catalytic e⁄ciency [17]. How-
ever, it should be noted that substitution of the active site Ser
of HFV PR to Thr did not cause a change in virion infectivity
[5].
The fusion protein was processed with factor Xa. The ¢rst
11 residues of the processed PR was ISMNPLQLLQP^ as
Table 1
Oligopeptide substrates representing naturally occurring cleavage sites in retroviruses and retrotransposons tested as substrates of the HFV PR
No. Sequence Source Site Km (mM) kcat (s31) kcat/Km (mM31 s31)
1. SRAVN*TVTQS HFV Gag(NC)a 0.56 þ 0.10 0.006 þ 0.0005 0.011
2. WQHWEN*QVGHR HFV PR/RTb not determinedc
3. YEGVF*YTDGS HFV RT/RHb s 1.0d 0.001d
4. GSYVVN*CNTKK HFV RH/INb 0.91 þ 0.08 0.003 þ 0.0002 0.003
5. NGYVH*TVRTR Ty3 Gag(NC)e not hydrolyzed
6. SRAVY*TITPE Ty3 RT/INe 0.15 þ 0.05 0.001 þ 0.0002 0.007
7. SNVVS*TIQS Ty3 RT/INe not determinedc
8. TARAH*NVSTS Ty1 Gag(NC)f not hydrolyzed
9. VPTIN*NVHTS Ty1 PR/INf 0.03 þ 0.01 0.0002 þ 0.00003 0.007
10. IHLIA*AVKAV Ty1 IN/RTf 1.00 þ 0.16 0.002 þ 0.0002 0.002
11. ELECL*LSIPL BLV TF/PRg not hydrolyzed
12. PPMVG*VLDAP BLV PR/p13g not hydrolyzed
13. DSKAF*LATDQ MMTV pp21/p3g not hydrolyzed
14. DELIL*PVKRK MMTV p3/p8g not hydrolyzed
15. IQPLIM*AVVNR RSV X2/NCg not hydrolyzed
16. RATVL*TVALH RSV PRP/RTg not hydrolyzed
17. TFQAY*PLREA RSV RT/INg not hydrolyzed
18. VSQNY*PIVQ HIV-1 MA/CAg not hydrolyzed
19. KARVL*AEAMS HIV-1 CA/p2g not hydrolyzed
20. TATIM*MQRG HIV-1 p2/NCg not hydrolyzed
21. RPQNF*LQSRP HIV-1 p1/p6g not hydrolyzed
22. APQVL*PVMHP HTLV-1 MA/CAg not hydrolyzed
23. KTKVL*VVQPK HTLV-1 CA/NCg not hydrolyzed
aCleavage site determined by Pfrepper et al. [7].
bCleavage site determined by Pfrepper et al. [8].
cSmall degree of hydrolysis was observed at the indicated position during overnight incubation.
dFor this substrate no saturation of the enzyme was achieved within the studied substrate concentration range. The kcat/Km value was calcu-
lated from measurements performed in ¢rst-order kinetic conditions ([S]HKm).
eCleavage sites published by Kirchner and Sendmeyer [28].
f Cleavage sites published by Merkulov et al. [23].
gThese cleavage site peptides were substrates of the respective proteinases [11,15,18,22].
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determined by Edman degradation, verifying that the process-
ing occurred at the expected site. The PR contained two extra
amino acids (underlined) required to maintain the integrity of
XmnI and Factor Xa cleavage sites, not found in the viral
proteinase sequence. The e¡ect of the two extra residues is
expected to be negligible on the PR activity [18]. Speci¢c
activity of the processed HFV PR on the decapeptide sub-
strate was 110 þ 2% of the unprocessed enzyme as determined
at 0.2 mM substrate concentration in a duplicate measure-
ment. The processed fusion protein was puri¢ed from the
maltose binding protein by gel ¢ltration chromatography in
the presence of 4 M guanidine-HCl as shown in Fig. 2. The
PR was estimated to be 90% pure based on Coomassie stain-
ing, and reacted with rabbit anti-HFV PR antiserum (data not
shown). The puri¢ed PR was refolded by dialysis, however,
only residual activity was detected as compared to the non-
separated HFV PR (data not shown). The loss of activity after
processing from another type of fusion protein has also been
reported in the literature [7].
The activity of the foamy PR in the fusion with MBP was
strongly dependent on the ionic strength of the bu¡er as
shown in Fig. 4A, a common characteristics of retroviral
PRs [19]. The pH optimum of the fusion protein was also
determined at low and high ionic strength and found to be
6.6^6.8 (Fig. 4B). The processed enzyme gave an identical pH
pro¢le (data not shown).
The HFV PR was found to dimerize [8] and the enzyme is
expected to be active in the dimeric form, similar to other
retroviral proteinases [1]. Previous studies indicated the Ser
in place of Thr in the ‘¢reman’s grip’ formed by the active
site triplet may result in less stable dimers of retroviral pro-
teinases [20]. Activity measurements with the HFV PR re-
quired concentrated enzyme, which also suggested that besides
the low catalytic activity, the stability of the PR dimer could
also be low, as compared to other retroviral PRs. Therefore
the urea denaturation curves for the unprocessed fusion pro-
tein and the processed HFV PR were determined (Fig. 5). The
urea concentration leading to 50% loss in enzymatic activity
of both forms of enzyme was 0.75 M as compared to the 1.85
M for the HIV-1 PR [21].
Several oligopeptide substrates representing naturally oc-
curring cleavage sites in retroviruses were tested as substrates
of the HFV PR (Table 1). These substrates were previously
found to be properly hydrolyzed by their respective pro-
teinases [11,13,15,18,22]. Furthermore, all of these peptides
were also substrates of the HIV-1 PR ([11,13,15,22], our un-
published results), however, none of them were hydrolyzed by
the HFV enzyme (Table 1). Peptides representing cleavage
sites in yeast retrotransposons were also assayed, and four
out of the six tested were found to be cleaved by HFV PR
(Table 1).
4. Discussion
Unlike other mammalian retroviruses which encode the PR
in the Pol part of the Gag-Pol (Gag-Pro-Pol) polyproteins, the
HFV PR was found to be coded on a separate Pol gene and
transcribed from a spliced mRNA [3,4]. Sequence comparison
with the PRs of the other human retroviruses (Fig. 1), as well
as molecular modeling of the HFV PR based on the crystal
structure of several retroviral PRs (P. Bagossi, Gy. Fenyo«falvi
Fig. 2. Expression and puri¢cation of HFV proteinase. Analysis of
total cell lysate prepared from E. coli cells bearing the construct
pHFVPR-MBP before (lane 1) and after (lane 2) IPTG induction
are shown. The fusion protein was puri¢ed on an amylose column
(lane 3), processed with factor X (lane 4) then the processed PR
was puri¢ed by gel ¢ltration (lane 5). Rainbow protein markers
(Amersham) were also run for comparison (lane M). The gel was
stained with Coomassie blue.
Fig. 1. Sequence comparison of HIV-1, HTLV-1 and HFV proteinases. Alignment was made with the CLUSTAL W (1.74) program. Identical
amino acids are shown in bold. The active site aspartate is indicated by an asterisk. The cloned HFV proteinase contained two extra residues
(underlined) at the N-terminus to maintain XmnI and factor Xa cleavage sites.
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and J. To«zse¤r, unpublished results) suggested that HFV PR
structure starts with the initiator Met encoded by the spliced
mRNA, and should be at least 100^107 residues long. Muta-
genesis studies identi¢ed the Asp of the Pol as the active site
in the Pol fusion protein (see Fig. 1, [5]), however, the C-
terminal -Arg-Gly-Asn/Asp- conserved region characteristic
of the retroviral PR [1] is missing from the sequence (Fig.
1). Since the enzyme may contain a £anking sequence at the
C-terminus, similar to the case of HTLV-1 PR, we cloned a
141 amino acid long region of the Pol. Since the coded pro-
teinase was active on oligopeptide substrate (Fig. 2), and it
was ended at the same site as the PR fragment previously
found to be active on its polyprotein substrate [6], it appears
to contain the entire PR coding sequence.
Foamy viruses have several unusual features, and their rep-
lication in some aspects resembles that of hepadnaviruses
[3,4]. The higher pH optimum of the HFV PR may be related
to the replication cycle distinct from other retroviruses. Unlike
in other retroviruses, Gag does not appear to be e⁄ciently
cleaved into smaller proteins, rather it is processed at the C-
terminal end intracellularly, in preassembled cores [10]. This
may require a pH optimum which is close to the intracellular
pH. Another feature of the HFV PR is its low dimer stability,
determined by urea dissociation, as compared to the more
stable HIV-1 PR.
A similarity also exists between the processing pro¢le of
foamy viruses and yeast retrotransposons. Similar to HFV,
in the yeast retrotransposon Ty1, a p4 protein is C-terminally
cleaved from the NC domain, which processing is essential for
transposition [23]. Although the peptides representing retro-
transposon cleavage sites in the NC domain were not hydro-
lyzed (Table 1), three other peptides representing Pol cleavage
sites in yeast retrotransposons were cleaved by the HFV PR,
suggesting that the retrotransposon proteases and HFV PR
share similarities in speci¢city (Table 1). A common charac-
teristics of the cleaved substrates is that, with one exception,
both P2 and P2P residues are L branched. This is also true for
the other Gag cleavage sites which were determined very re-
cently [24]. However, this may only be part of the sequence
requirement, since other peptides having such residues at P2
and P2P (like peptides 5, 7, 14^16, 22^23 in Table 1) were not
substrates of the enzyme. Similar to other retroviral pro-
teinases the speci¢city of HFV PR may also be governed by
extended interactions between the substrate and the enzyme,
could be very complex, and strongly dependent on the context
of the substrate sequence.
Fig. 3. Cleavage of an oligopeptide substrate with HFV PR. Sub-
strate 1 of Table 1 was incubated in the presence (lower panel) or
absence (upper panel) of fusion protein for 1 h as described in Sec-
tion 2. After incubation the reaction mixture was separated by re-
versed-phase HPLC. Peaks were identi¢ed by amino acid analysis
and Edman degradation. P1: SRAVN; P2: TVTQS; S: uncleaved
substrate (SRAVNTVTQS).
Fig. 4. E¡ects of ionic strength and pH on the activity of recombi-
nant HFV PR. A: The activity of the MBP-HFV PR fusion protein
was assayed in the presence of various NaCl concentrations at pH
6.6. B: The activity of the MBP-HFV PR fusion protein was meas-
ured at the indicated pH as described in Section 2, in the presence
(b) or absence (a) of 1 M NaCl.
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The low catalytic e⁄ciency of the HFV proteinase is in line
with the lower speci¢c activities of the HFV RT and IN as
compared to those of other retroviruses [25,26]. As opposed to
other retroviruses, in which the Gag-Pol fusion protein is
present only in relatively smaller amounts as compared to
the Gag proteins, a signi¢cant amount of Pol is produced
by HFV-infected cells [27], which may be required to have
larger total concentrations of the active HFV enzymes.
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Fig. 5. Urea denaturation curves for recombinant HFV PR.
Changes in enzymatic activity were determined with substrate 1 of
Table 1 for the puri¢ed fusion protein (b) or processed proteinase
(a) as described in Section 2.
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